Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology tags : Clinical-trials-phase-ii save search
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | News | $6.835 0.22% 160K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | $11.5 -0.52% 170K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
jeuveau publication for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% 19K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.1 0.5% 730K
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | $267.41 1.77% 1.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
tezspire copd
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.6 1.28% 5.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
avb-101 first dementia for trial
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA S | $101.17 -0.81% 1.1M
|
Health Technology
|
| O: -0.59%
H: 2.09%
C: -1.74%
rna-3927 mrna therapy
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
cancer trial initiated
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.761 -4.05% 39K
|
Health Technology
|
| O: 2.25%
H: 4.0%
C: 1.0%
alg-0550 first therapeutics study
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | News | $395.0 0.39% 550K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
ARWR | $22.1 -2.26% 390K
|
Health Technology
|
| O: 1.14%
H: 5.63%
C: -0.39%
treatment pharmaceuticals study
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
DTIL | $9.86 -8.02% 140K
|
Health Technology
|
| O: 1.56%
H: 3.55%
C: 0.81%
precision approval arcus program trial
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
KZR | $0.79 0.31% 240K
|
Health Technology
|
| O: 1.09%
H: 3.74%
C: -1.52%
lupus life approval sciences trial china
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for ...
Published: 2024-02-22 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.6 1.28% 5.6M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
Sanofi Gets Phase II MS Win, Eyes $5B in Peak Annual Sales for Pipeline
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
sales pipeline sanofi
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
JNJ | News | $147.6 1.28% 5.6M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
PTGX | $25.125 -0.38% 170K
|
Health Technology
|
| O: -0.23%
H: 0.54%
C: -1.13%
jnj-2113 psoriasis study
J&J Touts Positive Phase III Results for Antibody in Autoimmune Disorders
Published: 2024-02-06 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.6 1.28% 5.6M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
antibody positive disorders results
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
ENSC | $0.5301 -8.64% 150K
|
Health Technology
|
| O: 29.51%
H: 4.55%
C: -13.14%
pf614 fda positive treat meeting
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Published: 2024-01-24 (Crawled : 14:30) - biospace.com/
MBRX | News | $4.52 -0.08% 5K
|
Health Technology
|
| O: 7.31%
H: 9.8%
C: 3.51%
trials
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.